{
  "denotations": [
    {
      "id": "T1",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 0,
        "end": 6
      }
    },
    {
      "id": "T3",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 29,
        "end": 35
      }
    },
    {
      "id": "T6",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 66,
        "end": 72
      }
    },
    {
      "id": "T8",
      "obj": "Chemical",
      "span": {
        "begin": 150,
        "end": 158
      }
    },
    {
      "id": "T10",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 221,
        "end": 227
      }
    },
    {
      "id": "T11",
      "obj": "Chemical",
      "span": {
        "begin": 251,
        "end": 259
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "18252229_3",
  "text": "CYP2C9 ( * ) 2 ( p.R144C ) , CYP2C9 ( * ) 3 ( p.I359L ) , and the VKORC1 promoter ( g.-1639G-->A ) polymorphisms occur frequently in patients who are warfarin \" sensitive \" and require lower doses , whereas patients with VKORC1 missense mutations are warfarin \" resistant \" and require higher doses ."
}
